Rentosertib for idiopathic pulmonary fibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Jun 2023: Trial started, NCT05938920
  2. 11 Jul 2023: Trial registered, NCT05938920

The trials

NCT05938920: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

State
Completed
Phase
Phase 2
People
71 taking part
Started
19 Jun 2023
Primary completion
8 Aug 2024
Arms
INS018_055 30 mg QD, INS018_055 30 mg BID, INS018_055 60 mg QD
Results
Posted on the registry
  1. 19 Jun 2023: Trial started
  2. 11 Jul 2023: Trial registered
  3. 8 Aug 2024: Trial completed
  4. 2 Dec 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.